Soleo able to administer VYGART
By HME News Staff
Updated 8:34 AM CST, Tue January 25, 2022
FRISCO, Texas – Soleo Health has been selected as a limited distribution partner for VYGART by argenx SE. Effective immediately, Soleo Health is able to manage and administer VYVGART intravenously in the homes of patients or at its ambulatory infusion centers nationwide. “Soleo Health is at the forefront of bringing revolutionary specialty pharmaceuticals to patients nationwide with this new partnership with argenx,” said Drew Walk, Soleo Health CEO. “Our ever-growing limited drug distribution portfolio continues to expand as we are increasingly recognized for our capabilities, particularly within the autoimmune and neurology arenas.” The U.S. Food and Drug Administration approved VYGART on Dec. 17 for the treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) antibody positive. gMG affects approximately 36,000 to 60,000 people in the U.S., according to the Myasthenia Gravis Foundation of America, but it remains underdiagnosed in patients and its prevalence is likely higher. Soleo Health operates 21 locations throughout the U.S., with national nursing coverage and pharmacy licensure in 50 states, and is accredited by URAC, ACHC with Distinction in Rare Disease and Orphan Drugs, and The Joint Commission.
Comments